Last reviewed · How we verify
NCT05942456
Soluble B7-H3 as a Biomarker for Osteosarcoma
trial testing ELISA: enzyme-linked immunosorbent assay in Biomarker in 200 participants. Currently enrolling.
1 July 2024
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 5 June 2023 |
| Primary completion | 1 July 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- ELISA: enzyme-linked immunosorbent assay
Conditions studied
- Biomarker — all drugs for Biomarker →
- Progression — all drugs for Progression →
- Osteosarcoma — all drugs for Osteosarcoma →
- Surveillance — all drugs for Surveillance →
Sponsor
Peking University People's Hospital
Who can join
12 and older, any sex, with Biomarker or Progression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes.
Zhao Y, Sun K, Yu Y, Xu J, et al · · 2026 · PMID 41724790 · DOI 10.1038/s41598-026-40855-2
Verify or expand the search:
- PubMed search for NCT05942456
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Biomarker
Currently open trials in the same condition.
- NCT07088874 — Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy · recruiting
- NCT07165236 — Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor · recruiting
- NCT06483425 — A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer · active not recruiting
- NCT06276088 — Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy · recruiting
- NCT06307314 — Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05942456 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05942456.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing